Oncology

The proposed Most Favored Nation pricing model, which would have had a significant negative impact on cancer care in the United States, has been withdrawn by the Centers for Medicare & Medicaid Services.

This episode features Don Dizon, MD, discussing how LGBTQ+ patients with cancer navigate the world of cancer care, and the critical steps needed to improve their experiences.

An interim analysis demonstrated positive efficacy and safety in patients with metastatic solid tumors who were treated with etigilimab plus nivolumab.

Patients who have been diagnosed with acute graft-versus-host disease with high levels of amphiregulin could be at a higher risk for early mortality.

Black and Hispanic patients continue to be notably underrepresented in clinical cancer research, although research noted that participation is on the rise.

Investigators were able to identify breast cancer immunohistochemistry markers including Ki-67, estrogen receptor, and progesterone receptor status utilizing deep learning–based artificial intelligence algorithms

A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Late-stage cancer and poor outcomes for patients may occur as a result of low screening numbers during the COVID-19 pandemic.

Don Dizon, MD, FACP, FASCO, discusses the need to improve treatment strategies for transgender patients with cancer.

Investigators identified an association between the early expansion of Medicaid and a reduction in cancer-related mortality.

Aparna Parikh, MD, MS, discusses how her early experiences with physical fitness shaped her current relationship with exercise.

The Build Back Better Act could increase drug and related expenses could eventually lead to the closure of independent oncology practices.

Retrospective data suggest survival outcomes were positive and safety was reasonable for patients with cancer aged 80 years or older who received immune checkpoint inhibitors.

Findings from a Nationally Representative study indicated that multispecialty, academically affiliated, urban cancer institutions had more access to genetic testing.

The FDA approved nab-sirolimus as the first drug specifically indicated for the treatment of patients with malignant perivascular epithelioid cell tumors.

Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

ASTCT recently published an article in their journal Nucleus detailing the use of killer immunoglobulin-like receptor–ligand mismatch and its impact on graft versus host disease.

Currently, it is not known whether cisgender and transgender patients with cancer respond similarly to standard-of-care therapies due to challenges collecting gender identity and sexual orientation data in clinical cancer research.

The Partnership Director at GRYT Health opened up about their collaboration with Bristol Myers Squibb to address disparities in clinical trials.

Don Dizon, MD, emphasizes the importance of policies ensuring higher levels of gay and transgender participation in clinical cancer trials.

Use of a multidisciplinary geriatric assessment-driven intervention resulted in a reduction in grade 3 or higher chemotherapy-related toxic events.

Patients with advanced cancers who were ineligible for trials were more likely to receive frontline immune checkpoint inhibitor monotherapy than patients with the same advanced cancers who were eligible for trials.

ASTCT recently published an article in their journal Nucleus detailing the impact of genotype and voriconazole co-administration on tacrolimus trough concentration in pediatric β-thalassemia major patients following allogeneic hematopoietic stem cell transplantation.

ONCOLOGY® co-editor-in-chief Julie M. Vose, MD, MBA, recaps the 2021 Leadership, Empowerment, and Development Conference: Enriching and Supporting Women in Hematology and Oncology.

Eric D. Whitman, MD, discusses the clinical trial program at Atlantic Health System, a large nonprofit health care network in New Jersey, and how partnering with the Translational Genomics Research Institute will help to bring better care to patients with cancer.

CancerNetwork® sat down with C. Jillian Tsai, MD, PhD, at the 2021 American Society for Radiation Oncology to talk about why consolidative radiotherapy may be beneficial against oligoprogression in metastatic breast and lung cancer.

Join ASTCT for a series of webinars that focus on topics relating to CAR T.

CancerNetwork® spoke with Anthony W. Tolcher, MD, and Alexander I. Spira MD, PhD, about NEXT Oncology partnering with the Phase 1 Trials Program at Virginia Cancer Specialists to give patients another chance at treatment.